Halaven® (generic name: eribulin) is an anticancer chemotherapy agent – a microtubule dynamics inhibitor belonging to Halichondrin class with a unique mechanism of action. It is a structurally simplified synthetic analogue of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai. Halaven® exerts its effects by disrupting cell division, resulting in cell death.
Halaven® is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.
Halaven® is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline-containing therapy (unless unsuitable) for advanced or metastatic disease.
Dosage and Administration
Halaven® should be administered in units specialized in the administration of cytotoxic chemotherapy and only under the supervision of a qualified physician experienced in the appropriate use of cytotoxic medicinal products.
Halaven® is given by a short infusion into a vein over 2 to 5 minutes by a healthcare professional. Dosage is calculated based on the height and weight of an individual. Halaven® is given at 1.23mg/m2 (equivalent to 1.4mg/m2 eribulin mesilate) on Day 1 and 8 of every 21-day cycle. The dose and frequency of administration may vary, depending on the blood test results and the patient’s general health condition.
Dosage Form and Strengths
Each 2 ml vial contains 0.88mg eribulin equivalent to 1.0mg of eribulin mesilate.
Contraindications and Warnings
If patients have the following conditions, special precautions are needed before using Halaven®:
have known hypersensitivity to eribulin mesilate or its excipients.
have liver or kidney problems.
have heart problems, including a problem called “congenital long QT syndrome”.
are pregnant or plan to become pregnant.
are breastfeeding or planning to breastfeed.
are taking any prescription or non-prescription medicines, vitamins or herbal supplements.
have ever had low white blood counts or low platelet counts during previous anticancer treatments.
The most common adverse events associated with Halaven® are neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, constipation, leukopenia, decreased appetite, headache, diarrhea, vomiting, arthralgia, myalgia and pyrexia. Please refer to the full safety and prescribing information of Halaven® for dose delay and dose reduction recommendation.
Storage: Should be stored under 25°C
For further product information kindly refer to the prescribing information.
Eisai’s Financial Support Programme “ HOPE TO HER” for Breast Cancer Patients
HOPE TO HER – A Breast Cancer Drug Financial Assistance Programme
Breast cancer is the No. 1 cancer affecting woman in Hong Kong. One in every 15 females may have a chance to develop breast cancer before age 75. In 2016, there were over 4,100 new cases of breast cancer. In average, 11 new breast cancer cases are diagnosed and at least 1 patient died from the disease every day in 2016. 704 patients died from the disease in 2016. (1. Hong Kong Cancer Statistics 2016, Hong Kong Cancer Registry 2. Female Breast Cancer in 2016, Hong Kong Cancer Registry)
Prescription drugs can become a big financial burden for breast cancer patients. Eisai offers ‘HOPE TO HER’ – a breast cancer drug financial assistance programme, as a joint effort with Hong Kong Beast Cancer Foundation (HKBCF). This programme is dedicated to helping breast cancer patients who are financially challenged by their medication costs.
To learn more about the programme details, go to http://www.hkbcf.org or click the icon below:
Halaven® prescribing information, Hong Kong.
This is the website of Eisai (Hong Kong) Co. Ltd. This site is intended for Hong Kong residents only. The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions regarding patient care must be made with a health care provider, considering the unique characteristics of the patient.